1. • There were about 171 million people with diabetes in the world in
2000, and it is estimated that this number would increase to 366
million by 2030.
• As the number of persons with diabetes increases, the
development of microvascular complications such as chronic kidney
disease also rises.
• The early identification of chronic kidney disease provides
meaningful opportunities for effective reducing of the risk of
death, end-stage renal disease, or complications of renal
dysfunction.
• Microalbuminuria is an early sign of incipient renal disease, a
marker of its progression and is one of the most powerful
predictors of cardiovascular disease in nondiabetic individuals.
• To be useful, screening tests must be shown to be positive in >95%
of patients with albuminuria. We can find no documentation of any
test in which the sensitivity consistently reached 95% in more than
one study
THE PROBLEM

2. THE SOLUTION
• We have obtained recombinant albumin-binding
polypeptide. It is first used in the screening tests
for microalbuminuria
• All existing tests are based on the reaction of
"antigen-antibody", which can give a nonspecific
reaction
• The proposed test is based on the reaction of
"protein-protein"
• Our recombinant polypeptide provides high
specificity and doesn`t give false background
reactions

3. COMPETITIVE ADVANTAGES
• Differences from existing tests for
microalbuminuria:
– High specificity, allowing to obtain full quantitative
results;
– Getting rid of the stage of preparation of immune
sera;
– Applicability to biochips for mass screening and
monitoring of microalbuminuria

4. THE MARKET
• The global market of diagnostic for microalbuminuria is
estimated to be approximately $ 80 million and grows at 5-7%
per year
• Possible explosive growth of consumption in the pricing policy
aimed at radically reducing prices
• Our product will take at least 80% share of the existing
market, in view of the apparent competitive advantages
• Formation of the new market may be caused by lower prices
due to the lower costs, because only the high cost makes
compulsory test for microalbuminuria for the whole
population impossible now

5. OUR PROPOSALS
• We invite partners (it can be money makers
for clinical analysis of urine) and offer a license
for production of the screening tests for
microalbuminuria based on our recombinant
albumin-binding polypeptide
• We are ready to offer investors financing a full
production cycle of the screening tests for
microalbuminuria